Literature DB >> 6309346

Enterotoxemia in the goat: the humoral response and local tissue reaction following vaccination with two different bacterin-toxoids.

T E Blackwell, D G Butler, J A Bell.   

Abstract

A vaccination trial involving 72 goats was designed to compare the epsilon antitoxin titres and local reactions at the injection sites, of two commercial enterotoxemia vaccines. Three dosage regimens were used for each vaccine (12 goats per group). Although no significant differences were noted in humoral immune response between the two vaccines (P = 0.05), one vaccine regime resulted in low titres (P = 0.05) on two occasions. Local tissue reactions at injection sites persisted for six months in 53% of the goats regardless of vaccine used or dosage administered. No immunological basis for the reported differences in vaccine efficacy between sheep and goats was observed in this trial.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6309346      PMCID: PMC1235905     

Source DB:  PubMed          Journal:  Can J Comp Med        ISSN: 0008-4050


  2 in total

1.  The prevention of enterotoxaemia (pulpy kidney disease) by vaccination.

Authors:  B C Jansen
Journal:  Bull Off Int Epizoot       Date:  1967 Nov-Dec

2.  The production of a basic immunity against pulpy kidney disease.

Authors:  B C Jansen
Journal:  Onderstepoort J Vet Res       Date:  1967-04       Impact factor: 1.792

  2 in total
  8 in total

1.  Antibody response in goats vaccinated with liposome-adjuvanted Clostridium perfringens type D epsilon toxoid.

Authors:  F A Uzal; J P Wong; W R Kelly; J Priest
Journal:  Vet Res Commun       Date:  1999-05       Impact factor: 2.459

Review 2.  Enterotoxaemia in goats.

Authors:  F A Uzal; W R Kelly
Journal:  Vet Res Commun       Date:  1996       Impact factor: 2.459

3.  Clostridium perfringens type A and beta2 toxin associated with enterotoxemia in a 5-week-old goat.

Authors:  Tammy Dray
Journal:  Can Vet J       Date:  2004-03       Impact factor: 1.008

4.  The Myelin and Lymphocyte Protein MAL Is Required for Binding and Activity of Clostridium perfringens ε-Toxin.

Authors:  Kareem Rashid Rumah; Yinghua Ma; Jennifer R Linden; Myat Lin Oo; Josef Anrather; Nicole Schaeren-Wiemers; Miguel A Alonso; Vincent A Fischetti; Mark S McClain; Timothy Vartanian
Journal:  PLoS Pathog       Date:  2015-05-20       Impact factor: 6.823

5.  Clostridium perfringens Types A and D Involved in Peracute Deaths in Goats Kept in Cholistan Ecosystem During Winter Season.

Authors:  Riaz Hussain; Zhang Guangbin; Rao Zahid Abbas; Abu Baker Siddique; Mudassar Mohiuddin; Iahtasham Khan; Tauseef Ur Rehman; Ahrar Khan
Journal:  Front Vet Sci       Date:  2022-03-18

6.  Isolation of Clostridium perfringens type B in an individual at first clinical presentation of multiple sclerosis provides clues for environmental triggers of the disease.

Authors:  Kareem Rashid Rumah; Jennifer Linden; Vincent A Fischetti; Timothy Vartanian
Journal:  PLoS One       Date:  2013-10-16       Impact factor: 3.240

7.  Clostridium Perfringens Toxins Involved in Mammalian Veterinary Diseases.

Authors:  F A Uzal; J E Vidal; B A McClane; A A Gurjar
Journal:  Open Toxinology J       Date:  2010

Review 8.  Pre-clinical and Clinical Implications of "Inside-Out" vs. "Outside-In" Paradigms in Multiple Sclerosis Etiopathogenesis.

Authors:  Haley E Titus; Yanan Chen; Joseph R Podojil; Andrew P Robinson; Roumen Balabanov; Brian Popko; Stephen D Miller
Journal:  Front Cell Neurosci       Date:  2020-10-27       Impact factor: 5.505

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.